Key Stats for Abbvie Stock
- Past-Week Performance: -6.7%
- 52-Week Range: $164.4 to $244.8
- Current Price: $205.1
What Happened?
AbbVie (ABBV), a global biopharmaceutical company whose growth now rests on two immunology drugs rather than the $16 billion U.S. revenue hole left by Humira’s biosimilar competition, guided full-year 2026 sales to $67 billion after delivering a record $61.2 billion in 2025, with shares trading at $205.07 against a 52-week high of $244.81.
The February 4 Q4 2025 earnings call confirmed Skyrizi and Rinvoq, the company’s flagship immunology treatments for conditions ranging from psoriasis to Crohn’s disease, generated $25.9 billion in combined 2026 revenue and are already guiding to $31 billion this year, exceeding AbbVie’s own 2027 long-term target by $500 million six months ahead of schedule.
Skyrizi commands more than 45% total prescription share in the U.S. biologic psoriasis market and captures roughly 75% of frontline new patient starts in inflammatory bowel disease, a rate that held steady even after competitor Tremfya (Johnson and Johnson’s IL-23 inhibitor) entered the IBD market in 2025, confirming category expansion rather than share cannibalization.
Robert Michael, Chairman and Chief Executive Officer, stated on the Q4 2025 earnings call that “Skyrizi and Rinvoq… combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by $0.5 billion,” tying directly to the March 2 Phase 3 AFFIRM data showing Skyrizi subcutaneous induction achieved 60% endoscopic response versus 14% for placebo in Crohn’s disease, a result management called superior even to the already-approved intravenous formulation.
AbbVie’s Parkinson’s franchise, migraine portfolio, and immunology pipeline together point toward three separate $5 billion-plus peak sales clusters, supported by a tavapadon U.S. approval expected in Q3 2026, a Skyrizi subcutaneous Crohn’s label expected early 2027, and $18.5 billion in projected 2026 free cash flow funding both the dividend and more than 30 business development transactions totaling $8 billion over the past two years.
Wall Street’s Take on AbbVie Stock
The March 2 Skyrizi subcutaneous Crohn’s data, which showed 60% endoscopic response versus 14% for placebo, directly reinforces the $21.5 billion Skyrizi revenue guide for 2026 and accelerates the case for label expansion into early 2027.
AbbVie’s normalized EPS is projected to surge 45.4% to $14.54 in 2026 from $10.00 in 2025, driven by operating margin expanding to ~48.5% as Skyrizi and Rinvoq royalty and launch costs normalize against a $67 billion revenue base.
EBITDA margin is also forecasted to recover from 40.0% in 2025 to 49.8% in 2026 and 50.7% in 2027, reflecting the operating leverage that emerges when two fully launched drugs dominate their categories without Humira-level rebate drag.
Twenty-two of 32 analysts covering ABBV rate it a buy or outperform, with a mean price target of $249.14 representing 21.5% upside from the current $205.07, a consensus anchored to Skyrizi’s 75% frontline IBD capture rate and the Vyalev Parkinson’s launch hitting $1 billion this year.
The spread between the Street’s low target of $184.00 and high of $299.00 reflects a specific binary: the low assumes Icotyde, J&J’s newly approved oral psoriasis pill, materially erodes Skyrizi’s 45%-plus biologic market share, while the $299 high assumes AbbVie executes on subcutaneous Crohn’s approval, tavapadon U.S. launch in Q3 2026, and continued IBD share leadership.
What Does the Valuation Model Say?
The TIKR mid-case model prices ABBV at $319.43 by December 2030, assuming a 5.5% revenue CAGR and 41.6% net income margins, inputs grounded in management’s confirmed high single-digit growth guidance through 2029 and the $18.5 billion 2026 free cash flow target that funds both the dividend and pipeline investment.
The market prices ABBV at roughly 14x forward earnings despite a 45.4% EPS surge projected for 2026 alone, undervaluing the compounding effect of $31 billion in combined Skyrizi and Rinvoq revenue already ahead of the 2027 long-term target.
Free cash flow, forecast at $24.59 billion in 2026 and $28.24 billion in 2027, funds the $319.43 TIKR price target’s assumption that AbbVie sustains dividend growth and reinvests in 30-plus pipeline transactions without balance sheet strain.
Moreover, Michael’s confirmation that Vyalev, Skyrizi, and oral CGRPs are each tracking toward separate $5 billion-plus peak sales franchises signals a business the Street is still modeling as a single-drug story.
The primary risk to the TIKR model is Icotyde’s commercial uptake rate in psoriasis; if the oral option captures faster-than-expected share and erodes Skyrizi’s 45%-plus biologic TRx share, the $21.5 billion 2026 Skyrizi guide breaks.
Watch the Q1 2026 earnings call, where Skyrizi’s psoriasis in-play capture rate versus the pre-Icotyde baseline will confirm whether J&J’s oral approval is expanding the market or directly cannibalizing AbbVie’s core growth driver.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ABBV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
